{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:31Z","timestamp":1740144031039,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"gilead sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40258-022-00725-0","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T05:02:15Z","timestamp":1646974935000},"page":"371-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India"],"prefix":"10.1007","volume":"20","author":[{"given":"V.","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"725_CR1","volume-title":"Thinking about rationing","author":"R Klein","year":"2012","unstructured":"Klein R, Maybin J. Thinking about rationing. London: The King\u2019s Fund; 2012."},{"issue":"6","key":"725_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2471\/BLT.15.155721","volume":"94","author":"K Chalkidou","year":"2016","unstructured":"Chalkidou K, Glassman A, Marten R, et al. Priority-setting for achieving universal health coverage. Bull World Health Organ. 2016;94(6):462\u20137.","journal-title":"Bull World Health Organ"},{"key":"725_CR3","doi-asserted-by":"crossref","unstructured":"Wagstaff A, Bredenkamp C, Buisman LR. Progress toward the health MDGs. Are the poor being left behind? Washington: The World Bank Development Research Group; 2014.","DOI":"10.1596\/1813-9450-6894"},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/hec.3299","volume":"25","author":"V Wiseman","year":"2016","unstructured":"Wiseman V, Mitton C, Doyle-Waters MM, et al. Using economic evidence to set healthcare priorities in low-income and lower-middle-income countries: a systematic review of methodological frameworks. Health Econ. 2016;25:140\u201361.","journal-title":"Health Econ"},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/00019053-200321140-00001","volume":"21","author":"J Mauskopf","year":"2003","unstructured":"Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics. 2003;21:991\u20131000.","journal-title":"Pharmacoeconomics"},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/hec.4730020108","volume":"2","author":"K Gerard","year":"1993","unstructured":"Gerard K, Mooney G. QALY league tables: handle with care. Health Econ. 1993;2:59\u201364.","journal-title":"Health Econ"},{"issue":"1","key":"725_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S0266462310001194","volume":"27","author":"I Cleemput","year":"2011","unstructured":"Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71\u20136.","journal-title":"Int J Technol Assess Health Care"},{"issue":"51","key":"725_CR8","doi-asserted-by":"publisher","first-page":"12911","DOI":"10.1073\/pnas.1717161115","volume":"115","author":"JP Sevilla","year":"2018","unstructured":"Sevilla JP, Bloom DE, Cadarette D, Jit M, Lipsitch M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc Natl Acad Sci. 2018;115(51):12911\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"725_CR9","doi-asserted-by":"crossref","unstructured":"Chang AY, Horton S, Jamison DT. Benefit-cost analysis in disease control priorities. In Disease control priorities: improving health and reducing poverty (3rd ed). Washington, D.C.: The International Bank for Reconstruction and Development\/The World Bank; 2017.","DOI":"10.1596\/978-1-4648-0527-1_ch9"},{"issue":"441","key":"725_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaj2345","volume":"10","author":"DE Bloom","year":"2018","unstructured":"Bloom DE, Fan VY, Sevilla JP. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10(441):1\u20133.","journal-title":"Sci Transl Med"},{"key":"725_CR11","volume-title":"Applied discrete choice modeling","author":"DA Hensher","year":"1981","unstructured":"Hensher DA, Johnson LW. Applied discrete choice modeling. New York: Routledge; 1981."},{"key":"725_CR12","first-page":"105","volume-title":"Frontiers in econometrics","author":"D McFadden","year":"1973","unstructured":"McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1973. p. 105\u201342."},{"key":"725_CR13","unstructured":"Saraswat V, Norris S, de Knegt RJ, et al. Historical epidemiology of hepatitis c virus (hcv) in select countries\u2014vol. 2. J Viral Hepatitis. 2015:22(S1):6\u201325."},{"key":"725_CR14","unstructured":"Gilead Sciences, Inc. Chronic hepatitis c treatment expansion: generic manufacturing for developing countries. 2015."},{"issue":"1","key":"725_CR15","first-page":"98","volume":"60","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis c virus genotypes. Hepatology. 2015;60(1):98\u2013105.","journal-title":"Hepatology"},{"issue":"2","key":"725_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/1540-5885.320086","volume":"3","author":"AD Shocker","year":"1986","unstructured":"Shocker AD, Hall WG. Pretest market models: a critical evaluation. J Prod Innov Manag. 1986;3(2):86\u2013107.","journal-title":"J Prod Innov Manag"},{"key":"725_CR17","unstructured":"Rangan VK, Yong S. TruEarth healthy foods: Market research for a new product introduction. Boston: Harvard Business School Publishing, Brief Case 4065."},{"issue":"7","key":"725_CR18","doi-asserted-by":"publisher","first-page":"e0252764","DOI":"10.1371\/journal.pone.0252764","volume":"16","author":"DE Bloom","year":"2021","unstructured":"Bloom DE, Khoury A, Srinivasan V. Estimating the net value of treating hepatitis c virus using Sofosbuvir-velpatisvir in India. PLoS ONE. 2021;16(7):e0252764.","journal-title":"PLoS ONE"},{"issue":"11","key":"725_CR19","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the global burden of disease 2013 study. Lancet Glob Health. 2015;3(11):e712\u201323.","journal-title":"Lancet Glob Health"},{"issue":"9908","key":"725_CR20","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/S0140-6736(13)62105-4","volume":"382","author":"DT Jamison","year":"2013","unstructured":"Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382(9908):1898\u2013955.","journal-title":"Lancet"},{"key":"725_CR21","volume-title":"World development indicators","author":"World Bank","year":"2017","unstructured":"World Bank. World development indicators. Washington, DC: World Bank; 2017."},{"key":"725_CR22","doi-asserted-by":"crossref","unstructured":"Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis c virus (hcv) infections with today\u2019s treatment paradigm\u2014vol. 2. J Viral Hepatitis. 2015:22(1 Suppl.):26\u201345.","DOI":"10.1111\/jvh.12473"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: Initial estimates and the need for further research. Value Health. 2016;19:929\u201335.","journal-title":"Value Health"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.12688\/gatesopenres.13201.1","volume":"4","author":"YL Chi","year":"2020","unstructured":"Chi YL, Blecher M, Chalkidou K, et al. What next after GDP-based cost effectiveness thresholds? Gates Open Res. 2020;4:176.","journal-title":"Gates Open Res."},{"key":"725_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/0253-7613.36541","volume":"39","author":"AY Khan","year":"2007","unstructured":"Khan AY, Ghilzai NM. Counterfeit and substandard quality of drugs: the need for an effective and stringent regulatory control in India and other developing countries. Indian J Pharmacol. 2007;39:206\u20137.","journal-title":"Indian J Pharmacol"},{"key":"725_CR26","unstructured":"Nielsen Innovation Analytics. HCV product launch assessment in developing markets. 2015."},{"key":"725_CR27","unstructured":"Press Information Bureau. Shri J.P. Nadda launches national viral hepatitis control program. New Delhi: Ministry of Health and Family Welfare, Government of India, July 28, 2018."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-022-00725-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-022-00725-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-022-00725-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:14:11Z","timestamp":1650536051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-022-00725-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40258-022-00725-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"24 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilead Sciences, Inc. funded the initial work on this research project. Gilead has no editorial or other influence on the content of the authors\u2019 publication(s) resulting from the project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Either in his capacity as a faculty member at Harvard T.H. Chan School of Public Health or as a consultant to Data for Decisions, LLC., David Bloom has worked on valuation studies funded by grants from Gilead Life Sciences, Pfizer, GSK, Sanofi, Merck, and Edwards Life Sciences. He has also received fees or travel reimbursements from those entities and from Simpson Healthcare for providing consulting services or for speaking and participating in meetings and advisory boards. All three authors received funding from Gilead Sciences for the initial work on this research project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Physician Survey data were collected by A.C. Nielsen Inc. in India for Gilead Sciences, Inc. The study was \u201cdouble blind\u201d in that that nobody can find out who the respondents are, and the respondents did not know that Gilead was the sponsor of the research. The respondents were asked to assume all the data they saw were hypothetical and for market research only. The respondents\u2019 consent was obtained prior to collection of data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"For physician questionnaire data, please contact the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"None.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"David Bloom and V. Srinivasan contributed to the study conception and design. Material preparation and data collection were performed by A. C. Nielsen, Inc. Analysis was performed by all three authors. The first draft of the manuscript was written by V. Srinivasan. The other two authors commented on earlier versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}